cells

Mendus

OMX: IMMU

Market CapSEK463m

Last Close SEK2.32

Mendus is a clinical-stage immunoncology (IO) company based in Sweden and the Netherlands. The company specialises in allogeneic dendritic cell (DC) biology and currently has two lead, cell-based, off-the-shelf therapies for haematological and solid tumours.

More Mendus content >

Investment summary

In its Q322 report, Mendus highlighted key developments in the period, and some significant post-period events, as the company prepares to present key survival and immunomonitoring data from its cancer relapse vaccine, DCP-001, at the American Society of Hematology (ASH) 2022 conference in December. This data will be important in framing DCP-001’s clinical utility versus (and in combination with) the main competitor in acute myeloid leukaemia (AML) maintenance, azacitidine. Mendus’s Q322 financials held no surprises, therefore our forecasts for FY22 and FY23 are largely unchanged. With SEK250m of debt financing secured and a net cash position of SEK15.7m at end-Q322, we expect Mendus’s operations to be sufficiently funded into H224. We value Mendus at SEK1.8bn or SEK9.1 per share (previously SEK1.87bn or SEK9.35 per share).

Y/E Dec
Revenue (SEKm)
EBITDA (SEKm)
PBT (SEKm)
EPS (fd) (öre)
P/E (x)
P/CF (x)
2020A 0.0 (85.1) (89.2) (117.1) N/A N/A
2021A 0.0 (130.1) (133.4) (73.0) N/A N/A
2022E 3.2 (125.9) (130.9) (65.7) N/A N/A
2023E 0.0 (129.4) (138.5) (69.5) N/A N/A
Industry outlook

IO is a frenetic pharmaceutical development area with many clinical combination studies being conducted by pharmaceutical and biotech companies. Investors should expect relatively rich newsflow from this subsector over the next few years.

Last updated on 30/11/2022
Content on Mendus
Mendus – No surprises in Q3 as DCP-001 readout nears
Healthcare | research Update | 14 November 2022
test tube close up
Mendus – Funding to see through key inflection points
Healthcare | research Flash note | 27 October 2022
test tube close up
Mendus – Next steps in anticipation of positive data
Healthcare | research Flash note | 18 October 2022
test tube close up
View more
Register to receive research on Mendus as it is published
Share price graph
Balance sheet
Forecast net cash (SEKm) 25.9
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual 21.3 5.5 (55.8)
Relative* 13.3 0.1 (45.4)
52-week high/low SEK5.0/SEK1.8
*% relative to local index
Key management
Erik Manting CEO
Lotta Ferm CFO
Alex Karlsson-Parra CSO
Jeroen Rovers CMO
Leopold Bertea CTO